EUCTR2011-003530-13-GB进行中（未招募）1 期
Randomised phase II window study of short-term preoperative treatment with the PI3K inhibitor GDC-0941 plus Anastrozole versus Anastrozole alone in patients with ER-positive primary breast cancer - OPPORTUNE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 141
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Women must meet ALL of the following criteria:
- •Histologically-confirmed breast cancer involving a palpable tumour of any size, or a tumour with an ultrasound-assessed diameter of = 1.0 cm
- •Estrogen receptor (ER) positive tumours with =1% of tumour cells positive for ER on immunohistochemical staining or an immunhistochemistry score (Allred) of 3 or higher
- •*No prior systemic treatment regimens for the new primary breast cancer currently under investigation; prior treatment for previous breast cancer is allowed as long as it was completed at least 1 year prior to inclusion into this trial.*
- •Postmenopausal, defined as
- •1) age = 55y and 1y or more of amenorrhea, OR
- •2) age < 55y and 1y or more of amenorrhea, with an estradiol assay <20 pg/mL, OR
- •3) age < 55y with prior hysterectomy but intact ovaries with an estradiol level <20 pg/mL, OR
- •4) Status after bilateral oophorectomy (= 28 days prior to first study treatment).
- •Adequate hematologic function (ANC = 1500 cells/µl + platelet count = 100000/µl).
- •Serum creatinine concentration < 1.5 x ULN; AST, ALT, bilirubin level < 1.5 x ULN; Fasting plasma glucose level < 7.8 mmol/L.
- •ECOG performance status 0-2
- •Written informed consent prior to admission to the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 71
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
排除标准
- •Male gender
- •*Inflammatory breast cancer.*
- •HER2-positive tumours with 3+ intensity on IHC staining for HER2 or amplification of the HER2 gene on ISH.
- •Evidence of distant metastases.
- •*Previous systemic or local treatment for the new primary breast cancer currently under investigation (including surgery, radiotherapy, cytotoxic and endocrine treatments); prior treatment for previous breast cancer is allowed as long as it was completed at least 1 year prior to inclusion into this trial.*
- •*Previous systemic treatment for other neoplasms within 1 year prior to inclusion into this trial.*
- •Clinically significant pulmonary dysfunction.
- •Uncontrolled Type 1 or 2 diabetes mellitus (diabetic patients must have been on a stable regimen of oral anti-hyperglycemic therapy for at least 3 weeks duration and must have home monitoring levels without fasting blood glucose >8.9 mmol/L or hypoglycemia for one week prior to study entry)
- •Serious intercurrent medical or psychiatric illness, including serious active infection.
- •Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to study entry.
- •Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator’s opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
研究者
相似试验
进行中（未招募）
1 期
A window of opportunity study of enzalutamide (alone or in combination with exemestane) in patients with newly diagnosed breast cancer who are awaiting surgery for their cancer.Primary breast cancerMedDRA version: 18.0Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002001-37-ESQueen Mary University London219
进行中（未招募）
1 期
A window of opportunity study of enzalutamide (alone or in combination with exemestane) in patients with newly diagnosed breast cancer who are awaiting surgery for their cancer.EUCTR2014-002001-37-GBQueen Mary University London235
进行中（未招募）
1 期
A window of opportunity study of enzalutamide (alone or in combination with exemestane) in patients with newly diagnosed breast cancer who are awaiting surgery for their cancer.Primary breast cancerMedDRA version: 20.0Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002001-37-DEQueen Mary University London235
已完成
不适用
PRE-TREAT: A window study evaluating short term treatment with tamoxifen or letrozole in oestrogen receptive positive breast cancerCancer - BreastBreast cancerACTRN12614000695606Melbourne Health21
进行中（未招募）
1 期
A phase II trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDACPatients with pancreatic ductal adenocarcinomaMedDRA version: 21.0Level: LLTClassification code 10033602Term: Pancreatic adenocarcinoma resectableSystem Organ Class: 100000004864EUCTR2020-003080-26-ITFONDAZIONE GISCAD (GRUPPO ITALIANO PER LO STUDIO DEI CARCINOMI DELL'APPARATO DIGERENTE)261